



Albireo  
 10 Post Office Square  
 Suite 502 South  
 Boston, MA 02109  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

<b>NASDAQ: ALBO</b>	
Last Trade:	28.14
Trade Time:	3:59 PM ET Oct 20, 2017
Change:	0.65 <span style="color: green;">↑</span> (+2.365%)
Day Range	26.82 - 29.00
52-Week Range	14.00 - 37.69
Volume	31,529

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Albireo Pharma is a clinical-stage company focused through its operating subsidiary on the development of therapies for orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo's lead product candidate, A4250, is an ileal bile acid transporter (IBAT) inhibitor in development for pediatric cholestatic liver diseases, initially progressive familial intrahepatic cholestasis (PFIC). Albireo Pharma is headquartered in Boston, Massachusetts and its operating subsidiary is located in Gothenburg, Sweden.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Oct 20, 2017 [Final Results of Albireo's Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting@ 2017](#)
- Oct 16, 2017 [Albireo to Host KOL Event on Progressive Familial Intrahepatic Cholestasis](#)
- Oct 3, 2017 [Final Results of Albireo's Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting@ 2017](#)
- Sep 28, 2017 [Albireo Elects Roger Jeffs to Board of Directors](#)
- Sep 26, 2017 [EMA's Paediatric Committee Agrees to Albireo's A4250 Pediatric Investigation Plan](#)

## Financials [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 27, 2017 [Annual Report \(10-K\)](#)
- Apr 21, 2017 [Proxy Statement \(DEF 14A\)](#)
- Aug 21, 2017 [Quarterly Report \(10-Q\)](#)
- May 11, 2017 [Quarterly Report \(10-Q\)](#)